Entities / Company
Editas Medicine.
discovery-phase pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 44
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
-
Investors are weighing risk and valuation factors for stocks traded on the Nasdaq electronic stock exchange.Some support1 report
-
ImmunityBio and Editas Medicine are competing for investment funding as healthcare companies.Some support1 report
-
TD Cowen restated a buy rating on Editas Medicine, which also disclosed insider sales to the SEC.Some support1 report
Gone quiet
No new reports in 90+ days-
Broken String Biosciences is seeking streamlined FDA approval for its INDUCE-seq platform, alongside executive changes.Some support2 reports
-
Editas Medicine and Bristol Myers Squibb announced a collaboration on June 27, 2025, to develop new therapies together.Speculative1 report
-
Editas Medicine and Bristol Myers Squibb triggered a milestone payment related to their collaboration.Some support1 report
-
Editas Medicine is developing oncology products in collaboration with Bristol Myers Squibb.Some support1 report
-
Editas Medicine presented data at a Congress event, coinciding with investment advice linking AI stocks to Trump-era tariffs.Speculative1 report
-
Editas Medicine was noted to be part of the Medical sector and outperformed it on July 31, 2025.Some support1 report
-
Editas Medicine shares added 73.2% on August 13, 2025, significantly outpacing the S&P 500's 8.4% gain.Some support1 report
-
Editas Medicine became the exclusive licensee of Broad Institute's Cas12a patent estate.Some support2 reports
-
Editas Medicine established its headquarters in Cambridge, Massachusetts, on September 2, 2025.Some support1 report
-
Editas Medicine sought regulatory feedback from the FDA on clinical trials and listed its shares on an exchange on May 27, 2026.Some support4 reports
No events began in the chosen period. Widen it, or reset.
Around Editas Medicine this week
News at the entities that move Editas Medicine most-
Nasdaq StructuralLKQ Corporation is involved in stock trades on the Nasdaq exchange, concurrent with a lawsuit announced from its New York City office.Moves Editas Medicine
-
TD Cowen Mentioned togetherWendy's is being analyzed for privatization prospects by TD Cowen amid Middle East war driving commodity price surges.Moves Editas Medicine
-
Iovance Biotherapeutics OperationalIovance Biotherapeutics and CAMP4 Therapeutics are being compared as healthcare companies.Moves Editas Medicine
-
MarketBeat Mentioned togetherMarketBeat released analyst recommendations for small-cap communication services companies Optimum Communications and Criteo.Moves Editas Medicine
-
FDA StructuralBioTech generated encouraging early data for MASH and POTS, and expects an FDA decision regarding cemdisiran next month.Moves Editas Medicine
-
SEC StructuralExecutives face claims regarding SEC filings, and Millrose spun off from Lennar Corporation.Moves Editas Medicine
Connections
The 12 strongest of 44, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
SEC Structural
Editas Medicine is required to file financial results and disclose insider transactions with the SEC.
-
Broad Institute Structural
Editas Medicine is an exclusive licensee of patents and patent estates held by the Broad Institute.
-
Nasdaq Structural
Editas Medicine is formally listed and trades its shares on the Nasdaq stock exchange.
-
Iovance Biotherapeutics Operational
The two companies are viewed as competitors in the market, facing joint evaluation from investors based on risk and valuation.
-
TD Cowen Mentioned together
TD Cowen provides financial ratings and research notes on Editas Medicine.
-
FDA Structural
one depends on the other
-
Cambridge Shared context
same place or sector
-
MarketBeat Mentioned together
MarketBeat provides financial data and analyst ratings covering Editas Medicine's stock performance.
Show all 12 connections
-
Bruce Transactional
Bruce held a former executive role at Editas Medicine.
-
Medical Shared context
Editas Medicine operates within the context of the Medical sector.
-
New Orleans Shared context
Editas Medicine presented data at an ASGCT meeting held in New Orleans.
-
ImmunityBio Operational
Both healthcare companies are actively competing for investment capital.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
2 eventsAugust 2026
1 eventShow 1 earlier month
June 2026
10 events- Broken String Biosciences is seeking streamlined FDA approval for its INDUCE-seq platform, alongside executive changes.
- Editas Medicine and Bristol Myers Squibb announced a collaboration on June 27, 2025, to develop new therapies together.
- Editas Medicine and Bristol Myers Squibb triggered a milestone payment related to their collaboration.
- Editas Medicine is developing oncology products in collaboration with Bristol Myers Squibb.
- Editas Medicine presented data at a Congress event, coinciding with investment advice linking AI stocks to Trump-era tariffs.
- Editas Medicine was noted to be part of the Medical sector and outperformed it on July 31, 2025.
- Editas Medicine shares added 73.2% on August 13, 2025, significantly outpacing the S&P 500's 8.4% gain.
- Editas Medicine became the exclusive licensee of Broad Institute's Cas12a patent estate.
- Editas Medicine established its headquarters in Cambridge, Massachusetts, on September 2, 2025.
- Editas Medicine sought regulatory feedback from the FDA on clinical trials and listed its shares on an exchange on May 27, 2026.